Tas-102
Recurrent Skin Carcinoma
National Cancer Institute (NCI)unclassifiedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Recurrent Skin Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
Binimetinib H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
Larotrectinib National Cancer Institute (NCI) | Phase 2 | CCC |
Crizotinib National Cancer Institute (NCI) | Phase 2 | CCC |
GSK-2636771 National Cancer Institute (NCI) | Phase 2 | CCC |
View all 34 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →